Phase 2 Start~month

Phase 2 Start: A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subre

Drug
leber
Indication
Leber Congenital Amaurosis; LCA5; Leber Congenital Amaurosis (LCA)

Other upcoming events for IRD

Phase 2 ReadoutPhase 2 Readout: pipeline candidate
Phase 2 ReadoutPhase 2 Readout: opgx-lca5

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subre — IRD Phase 2 Start | BioSniper